MedPath

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2
Completed
Conditions
Melanoma
Neoplasm Metastasis
Registration Number
NCT00055562
Lead Sponsor
Celgene Corporation
Brief Summary

Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
274
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

UPMC Cancer Pavillion

🇺🇸

Pittsburgh, Pennsylvania, United States

Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Cancer Care Manitoba

🇨🇦

Winnipeg, Manitoba, Canada

The Harold Lever Regional Cancer Center

🇺🇸

Waterbury, Connecticut, United States

Washington University School of Medicine

🇺🇸

St. Louis, Missouri, United States

University of Southern California Norris Cancer Center

🇺🇸

Los Angeles, California, United States

Spectrum Health

🇺🇸

Grand Rapids, Michigan, United States

University of Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Carle Clinic

🇺🇸

Urbana, Illinois, United States

Mount Sinai Comprehensive Cancer Center

🇺🇸

Miami Beach, Florida, United States

Lutheran General

🇺🇸

Park Ridge, Illinois, United States

Lakeland Regional Cancer Center

🇺🇸

Lakeland, Florida, United States

Outpatient Clinic

🇺🇸

Santa Monica, California, United States

Beth Israel Deaconess Medical Ctr

🇺🇸

Boston, Massachusetts, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Melanoma Center of St Louis

🇺🇸

St. Louis, Missouri, United States

Ellis Fischel Cancer Center

🇺🇸

Columbia, Missouri, United States

UCLA

🇺🇸

Los Angeles, California, United States

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

L'Hotel Dieu de Quebec

🇨🇦

Quebec, Canada

St. Francis Memorial Hospital

🇺🇸

San Francisco, California, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

The Linder Clinical Trial Center

🇺🇸

Cincinnati, Ohio, United States

Sarah Cannon Cancer Center

🇺🇸

Nashville, Tennessee, United States

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Biomedical Research Alliance of New York

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Tom Baker Cancer Center

🇨🇦

Calgary, Alberta, Canada

Qell Health Sciences Center

🇨🇦

Halifax, Nova Scotia, Canada

© Copyright 2025. All Rights Reserved by MedPath